KR20050086933A - 브롬화수소산에스시탈로프람 및 이의 제조방법 - Google Patents

브롬화수소산에스시탈로프람 및 이의 제조방법 Download PDF

Info

Publication number
KR20050086933A
KR20050086933A KR1020057011704A KR20057011704A KR20050086933A KR 20050086933 A KR20050086933 A KR 20050086933A KR 1020057011704 A KR1020057011704 A KR 1020057011704A KR 20057011704 A KR20057011704 A KR 20057011704A KR 20050086933 A KR20050086933 A KR 20050086933A
Authority
KR
South Korea
Prior art keywords
escitalopram
disorder
treatment
escitalopram hydrobromide
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057011704A
Other languages
English (en)
Korean (ko)
Inventor
로렌스 마텔
로베르트 단세르
한스 페테르센
페테르 엘레가르
Original Assignee
하. 룬트벡 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32668635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20050086933(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 하. 룬트벡 아크티에 셀스카브 filed Critical 하. 룬트벡 아크티에 셀스카브
Publication of KR20050086933A publication Critical patent/KR20050086933A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020057011704A 2002-12-23 2003-12-18 브롬화수소산에스시탈로프람 및 이의 제조방법 Ceased KR20050086933A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200202005 2002-12-23
DKPA200202005 2002-12-23

Publications (1)

Publication Number Publication Date
KR20050086933A true KR20050086933A (ko) 2005-08-30

Family

ID=32668635

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057011704A Ceased KR20050086933A (ko) 2002-12-23 2003-12-18 브롬화수소산에스시탈로프람 및 이의 제조방법

Country Status (32)

Country Link
US (1) US20040167209A1 (cg-RX-API-DMAC7.html)
EP (1) EP1578738B1 (cg-RX-API-DMAC7.html)
JP (2) JP4658613B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050086933A (cg-RX-API-DMAC7.html)
CN (1) CN100349885C (cg-RX-API-DMAC7.html)
AR (1) AR042652A1 (cg-RX-API-DMAC7.html)
AT (1) ATE388947T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003287919B2 (cg-RX-API-DMAC7.html)
BR (1) BR0317623A (cg-RX-API-DMAC7.html)
CA (1) CA2511142A1 (cg-RX-API-DMAC7.html)
CY (1) CY1107451T1 (cg-RX-API-DMAC7.html)
DE (1) DE60319739T2 (cg-RX-API-DMAC7.html)
DK (1) DK1578738T3 (cg-RX-API-DMAC7.html)
EA (1) EA013116B1 (cg-RX-API-DMAC7.html)
EG (1) EG24729A (cg-RX-API-DMAC7.html)
ES (1) ES2298595T3 (cg-RX-API-DMAC7.html)
IL (1) IL169125A0 (cg-RX-API-DMAC7.html)
IS (1) IS2654B (cg-RX-API-DMAC7.html)
ME (1) MEP5808A (cg-RX-API-DMAC7.html)
MX (1) MXPA05005772A (cg-RX-API-DMAC7.html)
MY (1) MY135468A (cg-RX-API-DMAC7.html)
NO (1) NO20053595L (cg-RX-API-DMAC7.html)
NZ (1) NZ540281A (cg-RX-API-DMAC7.html)
PE (1) PE20040924A1 (cg-RX-API-DMAC7.html)
PL (1) PL378275A1 (cg-RX-API-DMAC7.html)
PT (1) PT1578738E (cg-RX-API-DMAC7.html)
RS (1) RS51092B (cg-RX-API-DMAC7.html)
TW (1) TW200501943A (cg-RX-API-DMAC7.html)
UA (1) UA80170C2 (cg-RX-API-DMAC7.html)
UY (1) UY28148A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004056791A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200504109B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200067152A (ko) * 2017-10-09 2020-06-11 테바 파마슈티컬 인더스트리즈 리미티드 에스시탈로프람의 새로운 염 및 고상형

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
NZ540281A (en) * 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
NZ549100A (en) * 2004-03-05 2010-02-26 Lundbeck & Co As H Crystalline composition containing escitalopram oxalate
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI358407B (en) * 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
KR20080080094A (ko) * 2005-10-14 2008-09-02 하. 룬트벡 아크티에 셀스카브 에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
EP2042499B1 (en) * 2006-07-11 2018-06-27 Mitsubishi Tanabe Pharma Corporation Salt of a morpholine compound
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
FR3006594A1 (fr) * 2013-06-11 2014-12-12 Sorin Crm Sas Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
US20240100012A1 (en) 2021-01-18 2024-03-28 Mark Hasleton Pharmaceutical dosage form

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34712A (en) * 1862-03-18 James h
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
WO2000023431A1 (en) * 1998-10-20 2000-04-27 H. Lundbeck A/S Method for the preparation of citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
HK1043129B (zh) * 1999-10-25 2004-10-21 H‧隆德贝克有限公司 西酞普蘭的製備方法
JP2002020379A (ja) * 2000-05-02 2002-01-23 Sumika Fine Chemicals Co Ltd シタロプラム臭化水素酸塩の結晶およびその結晶化方法
US6977306B2 (en) * 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
CA2353693C (en) * 2000-08-10 2003-07-22 H. Lundbeck A/S Pharmaceutical composition containing citalopram
ES2223959T3 (es) * 2000-12-04 2005-03-01 Westfalia Separator Ag Procedimiento de pretratamiento de aceites en bruto y grasas en bruto para la produccion de esteres de acidos grasos.
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
NZ540281A (en) * 2002-12-23 2008-07-31 Lundbeck & Co As H Escitalopram hydrobromide and a method for the preparation thereof
US20050174782A1 (en) * 2003-03-25 2005-08-11 Chapman Leonard T. Flashlight

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200067152A (ko) * 2017-10-09 2020-06-11 테바 파마슈티컬 인더스트리즈 리미티드 에스시탈로프람의 새로운 염 및 고상형

Also Published As

Publication number Publication date
NZ540281A (en) 2008-07-31
MXPA05005772A (es) 2005-08-16
ES2298595T3 (es) 2008-05-16
EP1578738B1 (en) 2008-03-12
EG24729A (en) 2010-06-21
CA2511142A1 (en) 2004-07-08
EA013116B1 (ru) 2010-02-26
IL169125A0 (en) 2009-02-11
BR0317623A (pt) 2005-11-29
US20040167209A1 (en) 2004-08-26
MEP5808A (xx) 2010-02-10
DE60319739D1 (de) 2008-04-24
JP2006514952A (ja) 2006-05-18
ZA200504109B (en) 2006-08-30
MY135468A (en) 2008-04-30
AR042652A1 (es) 2005-06-29
AU2003287919A1 (en) 2004-07-14
JP2011037893A (ja) 2011-02-24
UA80170C2 (en) 2007-08-27
ATE388947T1 (de) 2008-03-15
CY1107451T1 (el) 2012-12-19
RS51092B (sr) 2010-10-31
IS2654B (is) 2010-08-15
JP4658613B2 (ja) 2011-03-23
IS7848A (is) 2005-05-17
PL378275A1 (pl) 2006-03-20
UY28148A1 (es) 2004-09-30
AU2003287919B2 (en) 2009-11-12
DK1578738T3 (da) 2008-06-30
HK1087708A1 (en) 2006-10-20
RS20050487A (sr) 2007-06-04
CN1726202A (zh) 2006-01-25
PE20040924A1 (es) 2004-12-11
EP1578738A1 (en) 2005-09-28
NO20053595L (no) 2005-09-05
PT1578738E (pt) 2008-04-11
EA200501046A1 (ru) 2005-12-29
TW200501943A (en) 2005-01-16
WO2004056791A1 (en) 2004-07-08
DE60319739T2 (de) 2008-07-17
CN100349885C (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
JP2011037893A (ja) 臭化水素酸エスシタロプラム(escitalopramhydrobromide)およびその製造方法
AU2001100399A4 (en) Process for the preparation of pure citalopram
EP1181713B1 (en) Method for the preparation of pure citalopram
SK512004A3 (en) Process for the preparation of racemic citalopram and/or S- or R-citalopram by separation of a mixture of R- and S-citalopram
EA005491B1 (ru) Способ получения циталопрама
US8288568B2 (en) Process for the preparation of escitalopram
HK1087708B (en) Escitalopram hydrobromide and a method for the preparation thereof
KR20070083586A (ko) 시탈로프램 및 에난티오머의 제조 방법
JP6182183B2 (ja) デュロキセチン塩基及びデュロキセチン塩酸塩の製造方法
WO2003080589A1 (en) Purified citalopram salts
JPS5833872B2 (ja) ヘキサヒドロジベンゾフラン −3− オンノシンキナユウドウタイオヨビ ソノエンルイノセイゾウホウ

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050621

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20081031

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101222

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110228

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20101222

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I